Alexander Nyström Selected Research

Epidermolysis Bullosa Dystrophica (Dystrophic Epidermolysis Bullosa)

1/2022	Systemic Collagen VII Replacement Therapy for Advanced Recessive Dystrophic Epidermolysis Bullosa.
1/2022	Case Report: Diagnostic and Therapeutic Challenges in Severe Mechanobullous Epidermolysis Bullosa Acquisita.
1/2021	Mouse models for dominant dystrophic epidermolysis bullosa carrying common human point mutations recapitulate the human disease.
1/2021	Dystrophic Epidermolysis Bullosa: Secondary Disease Mechanisms and Disease Modifiers.
1/2021	QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
11/2019	Generation of rabbit polyclonal human and murine collagen VII monospecific antibodies: A useful tool for dystrophic epidermolysis bullosa therapy studies.
1/2019	Decorin counteracts disease progression in mice with recessive dystrophic epidermolysis bullosa.
10/2018	Collagen VII deficient mice show morphologic and histologic corneal changes that phenotypically mimic human dystrophic epidermolysis bullosa of the eye.
1/2018	Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa.
1/2018	Large Deletions Targeting the Triple-Helical Domain of Collagen VII Lead to Mild Acral Dominant Dystrophic Epidermolysis Bullosa.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alexander Nyström Research Topics

Disease

18	Epidermolysis Bullosa Dystrophica (Dystrophic Epidermolysis Bullosa) 01/2022 - 01/2013
9	Fibrosis (Cirrhosis) 01/2022 - 09/2015
9	Neoplasms (Cancer) 01/2021 - 01/2008
7	Wounds and Injuries (Trauma) 08/2021 - 01/2016
5	Inflammation (Inflammations) 05/2020 - 09/2015
3	Inborn Genetic Diseases (Disease, Hereditary) 01/2022 - 01/2016
3	Skin Diseases (Skin Disease) 01/2021 - 01/2013
3	Epidermolysis Bullosa 06/2019 - 01/2013
2	Cicatrix (Scar) 01/2022 - 01/2021
2	Muscular Dystrophies (Muscular Dystrophy) 08/2006 - 09/2005
1	Carcinoma (Carcinomatosis) 01/2022
1	Common Variable Immunodeficiency 01/2022
1	Autoimmune Lymphoproliferative Syndrome 01/2022
1	Epidermolysis Bullosa Acquisita (Acquired Epidermolysis Bullosa) 01/2022
1	Epidermolysis Bullosa Simplex (Epidermolysis Bullosa Herpetiformis Dowling Meara) 06/2019
1	Foot Deformities (Foot Deformity) 01/2019
1	Disease Progression 01/2019
1	Adenocarcinoma 01/2019
1	Congenital Abnormalities (Deformity) 01/2019
1	Hypertension (High Blood Pressure) 11/2018
1	Skin Manifestations 10/2018
1	Wound Infection (Wound Infections) 01/2018
1	Papilloma (Papillomatosis) 02/2016
1	Carcinogenesis 02/2016
1	Blister (Bulla) 11/2014
1	Male Infertility (Male Sterility) 09/2005

Drug/Important Bio-Agent (IBA)

17	CollagenIBA 01/2022 - 01/2013
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2013
4	IntegrinsIBA 01/2021 - 08/2006
4	Collagen Type VIIIBA 01/2019 - 11/2014
3	ProteomeIBA 10/2021 - 01/2018
2	Antisense OligonucleotidesIBA 01/2021 - 10/2016
2	DecorinIBA 01/2019 - 05/2009
2	Biological ProductsIBA 10/2018 - 01/2018
2	Collagen Type XVIIIBA 02/2016 - 01/2016
2	Laminin (Merosin)IBA 08/2006 - 09/2005
1	Extracellular Matrix ProteinsIBA 01/2022
1	Tiopronin (Thiola)FDA Link 08/2021
1	carbomerIBA 01/2021
1	Thrombospondin 1IBA 01/2021
1	Matrix Metalloproteinases (MMPs)IBA 01/2021
1	Cell Surface ReceptorsIBA 11/2020
1	AntibodiesIBA 11/2019
1	Protein AggregatesIBA 06/2019
1	Keratin-5 (Keratin 5)IBA 06/2019
1	Keratins (Keratin)IBA 06/2019
1	4-phenylbutyric acid (Buphenyl)FDA Link 06/2019
1	Peptide Hydrolases (Proteases)FDA Link 01/2019
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2019
1	Conditioned Culture MediaIBA 01/2019
1	DisintegrinsIBA 01/2019
1	Metalloproteases (Metalloproteinases)IBA 01/2019
1	Heparin-binding EGF-like Growth Factor (HB-EGF)IBA 01/2019
1	LigandsIBA 11/2018
1	EnzymesIBA 11/2018
1	Messenger RNA (mRNA)IBA 01/2018
1	Complement System Proteins (Complement)IBA 12/2017
1	RNA (Ribonucleic Acid)IBA 03/2016
1	Protein-Lysine 6-Oxidase (Lysyl Oxidase)IBA 02/2016
1	CarcinogensIBA 02/2016
1	Sirolimus (Rapamycin)FDA Link 01/2016
1	Interleukin-6 (Interleukin 6)IBA 09/2015
1	Losartan (Cozaar)FDA LinkGeneric 09/2015
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2013
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 11/2009
1	perlecanIBA 05/2009
1	Collagen Type XVIII (Type XVIII Collagen)IBA 05/2009
1	Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)IBA 05/2009
1	Proteoglycans (Proteoglycan)IBA 05/2009
1	AgrinIBA 05/2009
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2009
1	ErbB Receptors (EGF Receptor)IBA 05/2009
1	Small Leucine-Rich ProteoglycansIBA 05/2009
1	Integrin alpha2beta1IBA 01/2008
1	laminin alpha 2IBA 09/2005

Therapy/Procedure

10	Therapeutics 01/2022 - 01/2013
2	Cell- and Tissue-Based Therapy (Cell Therapy) 11/2019 - 11/2014
1	Injections 01/2022
1	Intradermal Injections 11/2014